Condition: Healthy · Sponsor: Medical University of Graz
One of the main problems in cardiac magnetic resonance (MR) investigations is the strong dependence of the achieved image quality on optimal settings of sequence parameters and anatomical and physiological situations and it is well known that the diagnostic impact of cardiac MR investigations crucially depends on the adaption of imaging protocols to patients' state and ability to cooperate. The aim of the present study is the evaluation and optimization of various 1.5 Tesla and 3 Tesla cardiac MR investigation protocols without application of contrast agent as well as the acquisition of normal values for new cardiac MR images techniques: * normal myocardial morphology: T1-, T2- and T2\*-weighted imaging and acquisition of normal values of magnetic relaxation times (sequence- and protocol dependent), * normal cardiac function: systolic and diastolic function (sequence- and protocol dependent), * cardiac anatomy and coronary artery imaging: feasibility to evaluate length, diameter and blood flow (sequence- and protocol dependent), * normal blood flow topologies in the heart and the surrounding great vessels: 2D- and 3D blood flow imaging and evaluation techniques (sequence- and protocol dependent).
This description comes directly from the study's public registry record.
Ursula Reiter, PhD · +43-316-385 · ursula.reiter@klinikum-graz.at
Michael Fuchsjäger, Prof. Dr. · +43-316-385 · michael.fuchsjaeger@medunigraz.at
Always discuss trial participation with your own doctor first.
| Medical Unitersity Graz, Department of Radiology, Division of General Radiology | Graz, Styria, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01728597